New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Insmed Incorporated
INSM
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

12B

Biotechnology

Next Earning date - 31 Oct 2024

12B

Biotechnology

Next Earning date - 31 Oct 2024

70.96USD
Shape-0.75 ( -1.05%)
favorite-chart

Relative Strenght

98
favorite-chart

Volume Buzz

-63%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

12%

Quote Panel

Shape
Updated October 27, 2024
1W -1.83 % 1M -2.79 % 3M -4.83 % 1Y 198.15 %

Key Metrics

Shape
  • Market Cap

    12.19B


  • Shares Outstanding

    171.85M


  • Share in Float

    167.85M


  • Dividende

    0


  • Earning Date

    31 Oct 2024


  • Price Target

    70.96


  • Average Volume

    1.75M


  • Beta

    1.107


  • Range

    21.92-80.53


  • Industry

    Biotechnology


  • Website

    https://www.insmed.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

37.11x

P/S Ratio

282.80x

P/B Ratio

34.6

Debt/Equity

-244.3%

Net Margin

$-5.4

EPS

How INSM compares to sector?

P/E Ratio

Relative Strength

Shape

INSM

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$537M

Shape494%

2025-Revenue

$4.38

Shape-126%

2025-EPS

$537M

Shape-194%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Goldman Sachs

initialise

Previous: Not converted

2022-04-27

Now: Buy

Zacks Investment Research

downgrade

Previous: Not converted

2022-04-26

Now: Sell

Cantor Fitzgerald

initialise

Previous: Not converted

2021-10-11

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-1.09
vs -0.96

Q4.22

arrow
arrow

N/A

-1.20
vs -0.95

Q1.23

arrow
arrow

N/A

-1.17
vs -0.80

Q2.23

arrow
arrow

N/A

-1.78
vs -0.80

Q3.23

arrow
arrow

N/A

-1.10
vs -1.09

Q4.23

arrow
arrow

N/A

-1.28
vs -1.20

Q1.24

arrow
arrow

N/A

-1.06
vs -1.17

Q2.24

arrow
arrow

N/A

-1.94
vs -1.78

Q3.24

arrow
arrow

N/A

-1.20
vs -1.10

Q4.24

arrow
arrow

N/A

-1.23
vs -1.28

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+45%

67.7M  vs 46.8M

Q4.22

arrow
arrow

+6%

59.3M  vs 56.1M

Q1.23

arrow
arrow

+23%

65.2M  vs 53.1M

Q2.23

arrow
arrow

+18%

77.2M  vs 65.2M

Q3.23

arrow
arrow

+17%

79.1M  vs 67.7M

Q4.23

arrow
arrow

+41%

83.7M  vs 59.3M

Q1.24

arrow
arrow

+16%

75.5M  vs 65.2M

Q2.24

arrow
arrow

+17%

90.3M  vs 77.2M

Q3.24

arrow
arrow

+18%

93.4M  vs 79.1M

Q4.24

arrow
arrow

+17%

98.3M  vs 83.7M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

+438%

4.38
vs -2.16

Q4.22

arrow
arrow

-182%

-1.82
vs 4.38

Q1.23

arrow
arrow

+358%

3.58
vs -1.82

Q2.23

arrow
arrow

+157%

1.57
vs 3.58

Q3.23

arrow
arrow

+55%

0.55
vs 1.57

Q4.23

arrow
arrow

+56%

0.56
vs 0.55

Q1.24

arrow
arrow

+34%

0.34
vs 0.56

Q2.24

arrow
arrow

-774%

-7.74
vs 0.34

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

240

240
vs 207

16%

Q4.22

arrow
arrow

232

232
vs 240

-3%

Q1.23

arrow
arrow

242

242
vs 232

4%

Q2.23

arrow
arrow

231

231
vs 242

-5%

Q3.23

arrow
arrow

264

264
vs 231

14%

Q4.23

arrow
arrow

291

291
vs 264

10%

Q1.24

arrow
arrow

328

328
vs 291

13%

Q2.24

arrow
arrow

435

435
vs 328

33%

Earnings Growth

Latest News